Search
Aripiprazole lauroxil
go.drugbank.com/drugs/DB14185ApprovedThe patients may receive Aristada Initio in combination with a single 30 mg oral dose of aripiprazole to achieve appropriate levels of aripiprazole more rapidly.
Citarinostat
go.drugbank.com/drugs/DB15449InvestigationalCitarinostat is under investigation in clinical trial NCT02886065 (A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM).
TG-1042
go.drugbank.com/drugs/DB18435InvestigationalTG-1042 (formerly known as ASN-002) is a recombinant adenovirus carrying the cDNA coding sequence for the human interferon gamma gene.
MB-107
go.drugbank.com/drugs/DB18566ExperimentalMB-107 consists of mobilized peripheral blood-derived autologous CD34+ hematopoietic stem cells that are genetically modified to express the IL2RG gene.
TPX-4589
go.drugbank.com/drugs/DB18604InvestigationalTPX-4589 is an antibody-drug conjugate composed of a humanized monoclonal antibody targeting CLDN18.2 and linker-payload MC-VC-PAB-MMAE.
Synonyms: Antibody drug conjugate composed of a humanized monoclonal antibody targeting CLDN18.2 and linker-payload MC-VC-PAB-MMAEPEG-uricase
go.drugbank.com/drugs/DB05321Investigationalporcine uricase (urate oxidase), which breaks down the uric acid deposits is being studied in Phase III clinical trials for the treatment of severe, treatment-refractory gout in the United States in 2006
Milatuzumab
go.drugbank.com/drugs/DB12943InvestigationalMilatuzumab has been used in trials studying the treatment of Lupus Nephritis, Multiple Myeloma (MM), GVHD (Acute or Chronic), Myelodysplastic Syndrome, and Chronic Lymphocytic Leukemia, among others.
MRK-003
go.drugbank.com/drugs/DB17015ExperimentalIt is the preclinical analog of [MK-0752], a drug in clinical development.[A252682]
Brentuximab
go.drugbank.com/drugs/DB05471InvestigationalSGN-30 received orphan drug designation from the FDA in July 2003 for Hodgkin lymphoma and in February 2004 for T-cell lymphomas. … Brentuximab (SGN-30) is an engineered monoclonal antibody (mAb) that reacts with significant affinity to the CD30 antigen, which is highly expressed on a variety of hematologic malignancies as compared